AnaptysBio Shares Rise on FDA Approval of Jemperli as First Immunotherapy for MSI-H/dMMR Rectal Cancer

FDA grants accelerated approval to Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending AnaptysBio stock higher on royalty potential.